Atlas Venture Life Science Advisors’s Akero Therapeutics AKRO Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-359,251	Closed	-$8.39M	–	17
2023 Q4	$8.39M	Hold	359,251	–	–	1%	12
2023 Q3	$18.2M	Sell	359,251 -235,000	-40%	-$10.9M	2.81%	11
2023 Q2	$27.7M	Hold	594,251	–	–	3.45%	11
2023 Q1	$22.7M	Hold	594,251	–	–	3.08%	10
2022 Q4	$32.6M	Sell	594,251 -400,000	-40%	-$17.1M	3.92%	9
2022 Q3	$33.9M	Sell	994,251 -1,238,000	-55%	-$18.9M	3.74%	9
2022 Q2	$21.1M	Hold	2,232,251	–	–	3.53%	8
2022 Q1	$31.7M	Hold	2,232,251	–	–	4%	8
2021 Q4	$47.2M	Buy	+2,232,251	New	+$49.5M	4.34%	7

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Atlas Venture Life Science Advisors's AKRO Position: Q1 2024 in Review

Atlas Venture Life Science Advisors sold out of Akero Therapeutics (AKRO) in Q1 2024, closing a stake of 359,251 shares — an estimated $8.39M sold.

Atlas Venture Life Science Advisors first reported a position in AKRO in Q4 2021 and held it in 9 quarters. The position peaked at $47.2M in Q4 2021. 173 funds tracked by Wall St. Rank hold AKRO as of Q1 2024.

Atlas Venture Life Science Advisors reported no remaining Akero Therapeutics position as of Q1 2024 after selling out during the quarter.
Atlas Venture Life Science Advisors sold 359,251 Akero Therapeutics shares in Q1 2024, an estimated $8.39M.
Atlas Venture Life Science Advisors first reported a position in Akero Therapeutics in Q4 2021 and held it in 9 quarters.
Atlas Venture Life Science Advisors's Akero Therapeutics position peaked at $47.2M in Q4 2021.
173 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2024.

Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2024, filed 6 May 2024.